Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER

Chaudhuri, K. Ray; Martinez‐Martín, Pablo; Antonini, Angelo; Brown, Richard G.; Friedman, Joseph H.; Onofrj, Marco; Surmann, Erwin; Ghys, Liesbet; Trenkwalder, Claudia

doi:10.1016/j.parkreldis.2013.02.018

Cited by 119 publications

(94 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, during the study the patients did not suffer from congestive heart failure. These results confirm previous evidences obtained in patients with idiopathic Parkinson's disease showing positive effect on motor control and behavioral disturbances [47][48][49][50][51][52][53][54][55] as well as a good safety of RTG [56]. On the whole, these outcomes highlight that transdermal RTG should be considered as a therapeutic option for the treatment of atypical parkinsonism.…”

Section: Transdermal Rtg As Treatment Option For Atypical Parkinsoniasupporting

confidence: 89%

Possible Treatments of Atypical Parkinsonism

Vito¹

2016

Challenges in Parkinson's Disease

View full text Add to dashboard Cite

Success in treating patients with atypical parkinsonism remains exceedingly low. It is particularly important for both neurologists and general practitioners to have a guideline in the actual possible cure options. This study reviews the limited available literature reporting treatment trials about treatment in parkinsonism. Various therapeutical approaches have been tried with rasagiline, immunoglobulin, autologous mesenchymal stem cells, davunetide, lithium, and tideglusib. Recently, transdermal rotigotine (RTG) has been proposed for the treatment of atypical parkinsonism, as well as deep brain stimulation (DBS) of the pedunculopontine nucleus (PPN) alone or combined with globus pallidus internus (Gpi) stimulation. The outcomes reviewed here highlight the need for the development of randomized, placebo-controlled trials to validate outcomes about rotigotine, DBS, and all other new therapies directed at altering the underlying biological mechanisms involved in the disease process.

show abstract

Section: Transdermal Rtg As Treatment Option For Atypical Parkinsoniasupporting

confidence: 89%

Possible Treatments of Atypical Parkinsonism

Vito¹

2016

Challenges in Parkinson's Disease

View full text Add to dashboard Cite

show abstract

“…[87][88][89] These fi ndings provide evidence of a behavioural spectrum disorder, ranging from a hyperdopaminergic syn drome (including impulse control disorders) to hypodopaminergic levels associated with apathy, anxiety, and depression, as described in the withdrawal dopaminergic syndromes. 83,[90][91][92][93] Besides the emotional-aff ective syndrome, apathy might also be associated with a disruption of cognitive func tions.…”

Section: Lesions and Neuroimagingmentioning

confidence: 84%

“…The average score on the SAS decreased from 21·4 (SD 4·0) to 9·9 (SD 6·1) after ropinirole-ie, an improvement of 54% (SD 24%; range 0-78%). Also in open-label studies, 87,131 and using non-specifi c scales for apathy, pramipexole and rotigotine have led to signifi cant improvements in the UPDRS-I motivational items (p<0·001) and the NonMotor Symptoms Scale (p=0·0003) (Level C, one Class II and two Class III studies).…”

Section: Treatment Of Apathy In Parkinson's Diseasementioning

confidence: 99%

Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment

Pagonabarraga

Kulisevsky

Strafella

et al. 2015

The Lancet Neurology

422

394

View full text Add to dashboard Cite

Normal maintenance of human motivation depends on the integrity of subcortical structures that link the prefrontal cortex with the limbic system. Structural and functional disruption of diff erent networks within these circuits alters the maintenance of spontaneous mental activity and the capacity of aff ected individuals to associate emotions with complex stimuli. The clinical manifestations of these changes include a continuum of abnormalities in goal-oriented behaviours known as apathy. Apathy is highly prevalent in Parkinson's disease (and across many neurodegenerative disorders) and can severely aff ect the quality of life of both patients and caregivers. Diff erentiation of apathy from depression, and discrimination of its cognitive, emotional, and auto-activation components could guide an individualised approach to the treatment of symptoms. The opportunity to manipulate dopaminergic treatment in Parkinson's disease allows researchers to study a continuous range of motivational states, from apathy to impulse control disorders. Parkinson's disease can thus be viewed as a model that provides insight into the neural substrates of apathy.

show abstract

“…10 Rotigotine induced a greater improvement in sleep quality, as recorded by the Parkinson's Disease Sleep Scale-2 (PDSS-2) compared with placebo. 10,11 However, no published trails have investigated the efficacy of rotigotine on RBD symptoms. The present exploratory open-label study was designed to observe clinical and video-polysomnographic changes to determine the efficacy of rotigotine on PD patients with RBD.…”

Section: Introductionmentioning

confidence: 99%

Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease

Wang

Yang

et al. 2016

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

Study Objectives: REM sleep behavior disorder (RBD) is a common manifestation of Parkinson disease (PD). In this study, we assessed the effects of rotigotine transdermal patch on RBD features in patients with PD. Methods:In this prospective open-label study, eleven PD patients with untreated RBD were administered rotigotine patches for up to seven months to ameliorate their parkinsonism. The severities of their RBD symptoms before and after rotigotine therapy were evaluated through patient and bed partner interviews, a validated evaluation scale (REM sleep behavior disorder questionnaire-Hong Kong, RBDQ-HK), and blinded assessments based on videopolysomnographic (VPSG) measure. Results: Rotigotine improved parkinsonism and subjective sleep quality in PD patients with RBD. The RBDQ-HK total score, especially the Factor 2 score, was decreased, which demonstrated that the subjective severity of RBD symptoms was improved after rotigotine treatment, especially the frequency and severity of abnormal RBD-related motor behaviors. The VPSG analyses showed that the total sleep time (TST) and stage 1% were increased and that the PLMS index was decreased. However, no differences in the RBD-related sleep measures were observed. Conclusions: The improved RBD symptoms and VPSG measures of PD patients in this study (TST, stage 1%, and PLMS index) suggest that, in PD, rotigotine may partially improve RBD-related symptoms. Rotigotine should be considered to be an optional drug for the treatment of RBD symptoms in PD.

show abstract

Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER

Cited by 119 publications

References 28 publications

Possible Treatments of Atypical Parkinsonism

Possible Treatments of Atypical Parkinsonism

Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment

Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease

Contact Info

Product

Resources

About